UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/890,549	05/08/2002	Y. Tom Tang	PF-0676 USN	4687

7590 11/04/2003

Incyte Genomics Inc
Legal Department
3160 Porter Drive
Palo Alto, CA 94304

EXAMINER	
KAM, CHIH MIN	
ART UNIT	**PAPER NUMBER**
1653	

DATE MAILED: 11/04/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/890,549	TANG ET AL.	
	Examiner	Art Unit	
	Chih-Min Kam	1653	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondenc address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☐ Responsive to communication(s) filed on _____ .

2a)☐ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) 1-23 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☐ Claim(s) _____ is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☒ Claim(s) 1-23 are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11)☐ The proposed drawing correction filed on _____ is: a)☐ approved b)☐ disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12)☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____ .

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) ☐ The translation of the foreign language provisional application has been received.

15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ .
4) ☐ Interview Summary (PTO-413) Paper No(s). _____ .
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other: .

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group 1, claims 1-6, 8, 10, 11, 15 and 16, drawn to an isolated polypeptide comprising an amino acid sequence related to SEQ ID NO:2, a pharmaceutical composition comprising the polypeptide, an isolated polynucleotide encoding a polypeptide related to SEQ ID NO:2 or a polynucleotide related to SEQ ID NO:14, a cell transformed with the polynucleotide, a method for producing a polypeptide related to SEQ ID NO:2, and a method for treating a disease or condition associated with decreased expression of functional LIPAP, comprising administering the pharmaceutical composition comprising the polypeptide.

Group 2, claims 1, 2 and 15, drawn to an isolated polypeptide comprising an amino acid sequence related to SEQ ID NO:3; a pharmaceutical composition comprising the polypeptide.

Group 3, claims 1, 2 and 15, drawn to an isolated polypeptide comprising an amino acid sequence related to SEQ ID NO:4; a pharmaceutical composition comprising the polypeptide.

Group 4, claims 1, 2 and 15, drawn to an isolated polypeptide comprising an amino acid sequence related to SEQ ID NO:6; a pharmaceutical composition comprising the polypeptide.

Group 5, claims 1, 2 and 15, drawn to an isolated polypeptide comprising an amino acid sequence related to SEQ ID NO:9; a pharmaceutical composition comprising the polypeptide.

Group 6, claims 1, 2 and 15, drawn to an isolated polypeptide comprising an amino acid sequence related to SEQ ID NO:10; a pharmaceutical composition comprising the polypeptide.

Group 7, claims 1, 2 and 15, drawn to an isolated polypeptide comprising an amino acid sequence related to SEQ ID NO:11; a pharmaceutical composition comprising the polypeptide.

Group 8, claims 1, 2 and 15, drawn to an isolated polypeptide comprising an amino acid sequence related to SEQ ID NO:12; a pharmaceutical composition comprising the polypeptide.

Group 9, claims 3-6, 8, 10 and 11, drawn to an isolated polynucleotide encoding a polypeptide or a polynucleotide related to SEQ ID NO:13, a cell transformed with the polynucleotide, a method for producing a polypeptide.

Group 10, claims 3-6, 8, 10 and 11, drawn to an isolated polynucleotide encoding a polypeptide related to SEQ ID NO:3 or a polynucleotide related to SEQ ID NO:15, a cell

transformed with the polynucleotide, a method for producing a polypeptide related to SEQ ID NO:3.

Group 11, claims 3-6, 8, 10 and 11, drawn to an isolated polynucleotide encoding a polypeptide related to SEQ ID NO:4 or a polynucleotide related to SEQ ID NO:16, a cell transformed with the polynucleotide, a method for producing a polypeptide related to SEQ ID NO:4.

Group 12, claims 3-6, 8, 10 and 11, drawn to an isolated polynucleotide encoding a polypeptide related to SEQ ID NO:6 or a polynucleotide related to SEQ ID NO:18, a cell transformed with the polynucleotide, a method for producing a polypeptide related to SEQ ID NO:6.

Group 13, claims 3-6, 8, 10 and 11, drawn to an isolated polynucleotide encoding a polypeptide related to SEQ ID NO:9 or a polynucleotide related to SEQ ID NO:21, a cell transformed with the polynucleotide, a method for producing a polypeptide related to SEQ ID NO:9.

Group 14, claims 3-6, 8, 10 and 11, drawn to an isolated polynucleotide encoding a polypeptide related to SEQ ID NO:10 or a polynucleotide related to SEQ ID NO:22, a cell transformed with the polynucleotide, a method for producing a polypeptide related to SEQ ID NO:10.

Group 15, claims 3-6, 8, 10 and 11, drawn to an isolated polynucleotide encoding a polypeptide related to SEQ ID NO:11 or a polynucleotide related to SEQ ID NO:23, a cell transformed with the polynucleotide, a method for producing a polypeptide related to SEQ ID NO:11.

Group 16, claims 3-6, 8, 10 and 11, drawn to an isolated polynucleotide encoding a polypeptide related to SEQ ID NO:12 or a polynucleotide related to SEQ ID NO:24, a cell transformed with the polynucleotide, a method for producing a polypeptide related to SEQ ID NO:24.

Group 17, claim 7, drawn to a transgenic organism comprising a recombinant polynucleotide having a promoter operably linked to a polynucleotide encoding a polypeptide related to SEQ ID NO:2.

Group 18, claim 7, drawn to a transgenic organism comprising a recombinant polynucleotide having a promoter operably linked to a polynucleotide encoding a polypeptide related to SEQ ID NO:3.

Group 19, claim 7, drawn to a transgenic organism comprising a recombinant polynucleotide having a promoter operably linked to a polynucleotide encoding a polypeptide related to SEQ ID NO:4.

Group 20, claim 7, drawn to a transgenic organism comprising a recombinant polynucleotide having a promoter operably linked to a polynucleotide encoding a polypeptide related to SEQ ID NO:6.

Group 21, claim 7, drawn to a transgenic organism comprising a recombinant polynucleotide having a promoter operably linked to a polynucleotide encoding a polypeptide related to SEQ ID NO:9.

Group 22, claim 7, drawn to a transgenic organism comprising a recombinant polynucleotide having a promoter operably linked to a polynucleotide encoding a polypeptide related to SEQ ID NO:10.

Group 23, claim 7, drawn to a transgenic organism comprising a recombinant polynucleotide having a promoter operably linked to a polynucleotide encoding a polypeptide related to SEQ ID NO:11.

Group 24, claim 7, drawn to a transgenic organism comprising a recombinant polynucleotide having a promoter operably linked to a polynucleotide encoding a polypeptide related to SEQ ID NO:12.

Group 25, claim 9, drawn to an isolated antibody which specifically binds to a polypeptide related to SEQ ID NO: 2.

Group 26, claim 9, drawn to an isolated antibody which specifically binds to a polypeptide related to SEQ ID NO: 3.

Group 27, claim 9, drawn to an isolated antibody which specifically binds to a polypeptide related to SEQ ID NO: 4.

Group 28, claim 9, drawn to an isolated antibody which specifically binds to a polypeptide related to SEQ ID NO: 6.

Group 29, claim 9, drawn to an isolated antibody which specifically binds to a polypeptide related to SEQ ID NO: 9.

Group 30, claim 9, drawn to an isolated antibody which specifically binds to a polypeptide related to SEQ ID NO: 10.

Group 31, claim 9, drawn to an isolated antibody which specifically binds to a polypeptide related to SEQ ID NO: 11.

Group 32, claim 9, drawn to an isolated antibody which specifically binds to a polypeptide related to SEQ ID NO: 12.

Group 33, claims 12-14, drawn to a method for detecting a target polynucleotide in a sample by detecting the hybridization complex of the target polynucleotide with a probe, where the nucleotide sequence is related to SEQ ID NO:13.

Group 34, claims 12-14, drawn to a method for detecting a target polynucleotide in a sample by detecting the hybridization complex of the target polynucleotide with a probe, where the nucleotide sequence is related to SEQ ID NO:14.

Group 35, claims 12-14, drawn to a method for detecting a target polynucleotide in a sample by detecting the hybridization complex of the target polynucleotide with a probe, where the nucleotide sequence is related to SEQ ID NO:15.

Group 36, claims 12-14, drawn to a method for detecting a target polynucleotide in a sample by detecting the hybridization complex of the target polynucleotide with a probe, where the nucleotide sequence is related to SEQ ID NO:16.

Group 37, claims 12-14, drawn to a method for detecting a target polynucleotide in a sample by detecting the hybridization complex of the target polynucleotide with a probe, where the nucleotide sequence is related to SEQ ID NO:18.

Group 38, claims 12-14, drawn to a method for detecting a target polynucleotide in a sample by detecting the hybridization complex of the target polynucleotide with a probe, where the nucleotide sequence is related to SEQ ID NO:21.

Group 39, claims 12-14, drawn to a method for detecting a target polynucleotide in a sample by detecting the hybridization complex of the target polynucleotide with a probe, where the nucleotide sequence is related to SEQ ID NO:22.

Group 40, claims 12-14, drawn to a method for detecting a target polynucleotide in a sample by detecting the hybridization complex of the target polynucleotide with a probe, where the nucleotide sequence is related to SEQ ID NO:23.

Group 41, claims 12-14, drawn to a method for detecting a target polynucleotide in a sample by detecting the hybridization complex of the target polynucleotide with a probe, where the nucleotide sequence is related to SEQ ID NO:24.

Group 42, claim 16, drawn to a method for treating a disease or condition associated with decreased expression of functional LIPAP, comprising administering the pharmaceutical composition comprising the polypeptide related to SEQ ID NO:3.

Group 43, claim 16, drawn to a method for treating a disease or condition associated with decreased expression of functional LIPAP, comprising administering the pharmaceutical composition comprising the polypeptide related to SEQ ID NO:4.

Group 44, claim 16, drawn to a method for treating a disease or condition associated with decreased expression of functional LIPAP, comprising administering the pharmaceutical composition comprising the polypeptide related to SEQ ID NO:6.

Group 45, claim 16, drawn to a method for treating a disease or condition associated with decreased expression of functional LIPAP, comprising administering the pharmaceutical composition comprising the polypeptide related to SEQ ID NO:9.

Group 46, claim 16, drawn to a method for treating a disease or condition associated with decreased expression of functional LIPAP, comprising administering the pharmaceutical composition comprising the polypeptide related to SEQ ID NO:10.

Group 47, claim 16, drawn to a method for treating a disease or condition associated with decreased expression of functional LIPAP, comprising administering the pharmaceutical composition comprising the polypeptide related to SEQ ID NO:11.

Group 48, claim 16, drawn to a method for treating a disease or condition associated with decreased expression of functional LIPAP, comprising administering the pharmaceutical composition comprising the polypeptide related to SEQ ID NO:12.

Group 49, claims 17 and 18, drawn to a method for screening a compound for effectiveness as an agonist of a polypeptide related to SEQ ID NO:2, and a pharmaceutical composition comprising the agonist compound identified by the method.

Group 50, claims 17 and 18, drawn to a method for screening a compound for effectiveness as an agonist of a polypeptide related to SEQ ID NO:3, and a pharmaceutical composition comprising the agonist compound identified by the method.

Group 51, claims 17 and 18, drawn to a method for screening a compound for effectiveness as an agonist of a polypeptide related to SEQ ID NO:4, and a pharmaceutical composition comprising the agonist compound identified by the method.

Group 52, claims 17 and 18, drawn to a method for screening a compound for effectiveness as an agonist of a polypeptide related to SEQ ID NO:6, and a pharmaceutical composition comprising the agonist compound identified by the method.

Group 53, claims 17 and 18, drawn to a method for screening a compound for effectiveness as an agonist of a polypeptide related to SEQ ID NO:9, and a pharmaceutical composition comprising the agonist compound identified by the method.

Group 54, claims 17 and 18, drawn to a method for screening a compound for effectiveness as an agonist of a polypeptide related to SEQ ID NO:10, and a pharmaceutical composition comprising the agonist compound identified by the method.

Group 55, claims 17 and 18, drawn to a method for screening a compound for effectiveness as an agonist of a polypeptide related to SEQ ID NO:11, and a pharmaceutical composition comprising the agonist compound identified by the method.

Group 56, claims 17 and 18, drawn to a method for screening a compound for effectiveness as an agonist of a polypeptide related to SEQ ID NO:12, and a pharmaceutical composition comprising the agonist compound identified by the method.

Group 57, claim 19, drawn to a method for treating a disease or condition associated with decreased expression of functional LIPAP, comprising administering a pharmaceutical composition comprising an agonist of the polypeptide related to SEQ ID NO:2.

Group 58, claim 19, drawn to a method for treating a disease or condition associated with decreased expression of functional LIPAP, comprising administering a pharmaceutical composition comprising an agonist of the polypeptide related to SEQ ID NO:3.

Group 59, claim 19, drawn to a method for treating a disease or condition associated with decreased expression of functional LIPAP, comprising administering a pharmaceutical composition comprising an agonist of the polypeptide related to SEQ ID NO:4.

Group 60, claim 19, drawn to a method for treating a disease or condition associated with decreased expression of functional LIPAP, comprising administering a pharmaceutical composition comprising an agonist of the polypeptide related to SEQ ID NO:6.

Group 61, claim 19, drawn to a method for treating a disease or condition associated with decreased expression of functional LIPAP, comprising administering a pharmaceutical composition comprising an agonist of the polypeptide related to SEQ ID NO:9.

Group 62, claim 19, drawn to a method for treating a disease or condition associated with decreased expression of functional LIPAP, comprising administering a pharmaceutical composition comprising an agonist of the polypeptide related to SEQ ID NO:10.

Group 63, claim 19, drawn to a method for treating a disease or condition associated with decreased expression of functional LIPAP, comprising administering a pharmaceutical composition comprising an agonist of the polypeptide related to SEQ ID NO:11.

Group 64, claim 19, drawn to a method for treating a disease or condition associated with decreased expression of functional LIPAP, comprising administering a pharmaceutical composition comprising an agonist of the polypeptide related to SEQ ID NO:12.

Group 65, claims 20 and 21, drawn to a method for screening a compound for effectiveness as an antagonist of a polypeptide related to SEQ ID NO:2, and a pharmaceutical composition comprising the antagonist compound identified by the method.

Group 66, claims 20 and 21, drawn to a method for screening a compound for effectiveness as an antagonist of a polypeptide related to SEQ ID NO:3, and a pharmaceutical composition comprising the antagonist compound identified by the method.

Group 67, claims 20 and 21, drawn to a method for screening a compound for effectiveness as an antagonist of a polypeptide related to SEQ ID NO:4, and a pharmaceutical composition comprising the antagonist compound identified by the method.

Group 68, claims 20 and 21, drawn to a method for screening a compound for effectiveness as an antagonist of a polypeptide related to SEQ ID NO:6, and a pharmaceutical composition comprising the antagonist compound identified by the method.

Group 69, claims 20 and 21, drawn to a method for screening a compound for effectiveness as an antagonist of a polypeptide related to SEQ ID NO:9, and a pharmaceutical composition comprising the antagonist compound identified by the method.

Group 70, claims 20 and 21, drawn to a method for screening a compound for effectiveness as an antagonist of a polypeptide related to SEQ ID NO:10, and a pharmaceutical composition comprising the antagonist compound identified by the method.

Group 71, claims 20 and 21, drawn to a method for screening a compound for effectiveness as an antagonist of a polypeptide related to SEQ ID NO:11, and a pharmaceutical composition comprising the antagonist compound identified by the method.

Group 72, claims 20 and 21, drawn to a method for screening a compound for effectiveness as an antagonist of a polypeptide related to SEQ ID NO:12, and a pharmaceutical composition comprising the antagonist compound identified by the method.

Group 73, claim 22, drawn to a method for treating a disease or condition associated with overexpression of functional LIPAP, comprising administering a pharmaceutical composition comprising an antagonist of the polypeptide related to SEQ ID NO:2.

Group 74, claim 22, drawn to a method for treating a disease or condition associated with overexpression of functional LIPAP, comprising administering a pharmaceutical composition comprising an antagonist of the polypeptide related to SEQ ID NO:3.

Group 75, claim 22, drawn to a method for treating a disease or condition associated with overexpression of functional LIPAP, comprising administering a pharmaceutical composition comprising an antagonist of the polypeptide related to SEQ ID NO:4.

Group 76, claim 22, drawn to a method for treating a disease or condition associated with overexpression of functional LIPAP, comprising administering a pharmaceutical composition comprising an antagonist of the polypeptide related to SEQ ID NO:6.

Group 77, claim 22, drawn to a method for treating a disease or condition associated with overexpression of functional LIPAP, comprising administering a pharmaceutical composition comprising an antagonist of the polypeptide related to SEQ ID NO:9.

Group 78, claim 22, drawn to a method for treating a disease or condition associated with overexpression of functional LIPAP, comprising administering a pharmaceutical composition comprising an antagonist of the polypeptide related to SEQ ID NO:10.

Group 79, claim 22, drawn to a method for treating a disease or condition associated with overexpression of functional LIPAP, comprising administering a pharmaceutical composition comprising an antagonist of the polypeptide related to SEQ ID NO:11.

Group 80, claim 22, drawn to a method for treating a disease or condition associated with overexpression of functional LIPAP, comprising administering a pharmaceutical composition comprising an antagonist of the polypeptide related to SEQ ID NO:12.

Group 81, claim 23, drawn to a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein the target polynucleotide comprises a sequence of SEQ ID NO:13.

Group 82, claim 23, drawn to a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein the target polynucleotide comprises a sequence of SEQ ID NO:14.

Group 83, claim 23, drawn to a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein the target polynucleotide comprises a sequence of SEQ ID NO:15.

Group 84, claim 23, drawn to a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein the target polynucleotide comprises a sequence of SEQ ID NO:16.

Group 85, claim 23, drawn to a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein the target polynucleotide comprises a sequence of SEQ ID NO:18.

Group 86, claim 23, drawn to a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein the target polynucleotide comprises a sequence of SEQ ID NO:21.

Group 87, claim 23, drawn to a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein the target polynucleotide comprises a sequence of SEQ ID NO:22.

Group 88, claim 23, drawn to a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein the target polynucleotide comprises a sequence of SEQ ID NO:23.

Group 89, claim 23, drawn to a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein the target polynucleotide comprises a sequence of SEQ ID NO:24.

The claims of these groups are directed to different inventions, which are not linked to form a single general concept. The claims in the different groups do not have in common the same or corresponding technical features. In particular, each group is directed to distinct chemical entities and/or methods which use different materials and produce different effects. Accordingly, the claims are not so linked by a special technical feature within the meaning of

PCT Rule 13.2 so as to form a single inventive concept and lack of unity is deemed proper.

Insofar as Groups 1-89 are directed to polypeptides, polynucleotides, methods of making polypeptides, and methods of use polypeptides and polynucleotides, each is defined by a sequence of amino acids and nucleotides that is independent and/or patentably distinct, one from the other.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

A telephone call was made to Diana Hamlet-Cox on October 20, 2003 to request an oral election to the above restriction requirement, but did not result in an election being made.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (703) 308-9437. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on (703) 308-2923. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 872-9306 for regular communications and (703) 308-4227 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Chih-Min Kam, Ph. D. CMK
Patent Examiner

***
October 20, 2003

Christopher S. F. Low
CHRISTOPHER S. F. LOW
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600